tradingkey.logo

Ainos Inc

AIMD
View Detailed Chart
3.200USD
-0.080-2.44%
Market hours ETQuotes delayed by 15 min
13.66MMarket Cap
LossP/E TTM

Ainos Inc

3.200
-0.080-2.44%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.44%

5 Days

-11.60%

1 Month

-9.35%

6 Months

+492.59%

Year to Date

+601.75%

1 Year

+627.27%

View Detailed Chart

TradingKey Stock Score of Ainos Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is low. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ainos Inc's Score

Industry at a Glance

Industry Ranking
233 / 407
Overall Ranking
463 / 4616
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Ainos Inc Highlights

StrengthsRisks
Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.
Growing
The company is in a growing phase, with the latest annual income totaling USD 20.73K.
Fairly Valued
The company’s latest PE is -0.72, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 15.03K shares, decreasing 57.77% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 9.28K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.38.

Ainos Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Ainos Inc Info

Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.
Ticker SymbolAIMD
CompanyAinos Inc
CEOMr. Chun-Hsien Tsai
Websitehttps://www.ainos.com/
KeyAI